Immune-related adverse events and the balancing act of immunotherapy
The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-01-01
|
Series: | Nature Communications |
Online Access: | https://doi.org/10.1038/s41467-022-27960-2 |